Related by context. Frequent words. (Click for all words.) 83 Initiates Phase II 81 Presents Positive 80 Completes Enrollment 79 FDA Accepts 77 FDA Clears 76 Files Shelf Registration Statement 75 Patient Enrollment 75 Drug Candidate 75 Generic Version 75 Develop Novel 75 Completes Tender Offer 74 Announces FDA Clearance 74 Announces Initiation 74 Reports Positive 74 Receives FDA Clearance 74 Announces Presentation 74 Q1 Loss Narrows 74 Initiates Phase 73 Inc Therapeutic Competitors 73 Single Dose 73 FDA Approves 73 submitted Biologics License 73 gets USFDA nod 73 Q3 Loss Widens 73 Commences Phase 73 Extends Tender Offer 73 Q2 Loss Narrows 73 Company Nasdaq PRGO 72 Phase III Clinical Trial 72 Initiate Phase 72 Q3 Loss Narrows 72 Q1 Loss Widens 72 Q4 Loss Narrows 72 please visit http:/www.supergen.com 72 Q2 Loss Widens 72 BioGlue R 72 Regains Compliance With 72 Cholesterol Drug 71 Q4 Loss Widens 71 Announces Stockholder Approval 71 Stockholders Approve Merger 71 Clinical Trial Results 71 R sorafenib tablets 71 Blood Thinner 71 Inc. NASDAQ QLTI 71 Provides Guidance 71 Declares Quarterly Dividends 71 PROFILE CO 71 Issues Guidance 71 www.combinatorx.com 71 Announces Positive 71 Updates Guidance 70 Pivotal Phase III 70 Seeks Approval 70 Receives Patent 70 Webcast Annual Meeting 70 Vytorin combines 70 Announces Successful Completion 70 Announces Dismissal 70 Regains Compliance 70 Vertex Pharmaceuticals Announces 70 Transcept Pharmaceuticals 70 Host Fourth Quarter 70 Calls Purchased 70 Acquires Exclusive 70 Pivotal Study 70 Announces Organizational Changes 70 Receives Positive 70 Shows Promise 70 Significantly Improves 70 phenylketonuria PKU developed 70 Hold Fourth Quarter 70 Puts Purchased 70 Medarex logo 70 Exercises Option 70 4Q Loss Widens 69 Movers Roundup 69 Exploit collaboration 69 Takeda Kyowa Hakko Kirin 69 Achieves Milestone 69 Preclinical Data 69 Significantly Reduces 69 Signs Licensing Agreement 69 Phase III Trial 69 Receives Regulatory 69 CEO Exercises Options 69 Inc. Nasdaq IMGN 69 Announces Additions 69 Director Exercises Options 69 Explore Strategic Alternatives 69 Bearish Pressure Building 69 Regulatory Disclosure 69 Reduces Risk 69 Cervical Cancer Vaccine 69 Recombinant Human 69 Hold Third Quarter 69 Pivotal Phase 69 CHEAP ONLINE PHARMACY LOW 69 FDA Warns 69 MKC# 69 Q2 Profit Surges